[Detection and evaluation of the role of sarcopenia in elderly patients with cancer treated with chemotherapy. ONCOSARCO project]

Rev Esp Geriatr Gerontol. 2017 May-Jun;52(3):146-151. doi: 10.1016/j.regg.2016.02.003. Epub 2016 Mar 22.
[Article in Spanish]

Abstract

Objectives: To develop a predictive model of toxicity to chemotherapy in elderly patients with cancer, using the variables associated with sarcopenia, and to identify which of these parameters, sarcopenia or frailty, is the best predictor of toxicity to chemotherapy in the elderly.

Material and methods: A prospective observational study with patients ≥70 years treated with chemotherapy in the Cancer Unit for the Elderly, in the Medical Oncology Section of the Hospital Virgen de la Luz de Cuenca. The following tests will be performed by each patient before chemotherapy: muscle strength (handgrip, cylindrical handgrip, pinch gauge, hip flexion, knee extension), muscle mass (skeletal muscle mass index), and physical function (gait speed and 5STS test). The occurrence of severe toxicity will be recorded over a period of 4 months of chemotherapy treatment. It will be evaluated, using logistic regression analysis, whether sarcopenia (defined by the European Working Group on Sarcopenia in Older People) or frailty (defined by the phenotype of frailty) is the best predictor of chemotherapy toxicity. Using a multinomial logistic regression analysis, we will try to create the first model to predict toxicity to chemotherapy in elderly patients with diagnosis of cancer, based on the definition of sarcopenia.

Conclusions: It is expected that the final analysis of this project will be useful to detect predictive factors of toxicity to chemotherapy in elderly patients with cancer.

Keywords: Anciano; Cancer; Chemotherapy; Cáncer; Elderly; Fragilidad; Frailty; Quimioterapia; Sarcopenia.

Publication types

  • Observational Study

MeSH terms

  • Aged
  • Antineoplastic Agents / adverse effects*
  • Female
  • Geriatric Assessment
  • Humans
  • Longitudinal Studies
  • Male
  • Neoplasms / complications*
  • Neoplasms / drug therapy*
  • Prospective Studies
  • Sarcopenia / complications*
  • Sarcopenia / diagnosis*

Substances

  • Antineoplastic Agents